"Piper took a look at Xoma and gave an opinion. What would you have them do WAIT until new developments to give their analyst's opinion?"
Just because they found a nice company and a nice technology in need for an opinion, no problem, now give me the extra motives.
Does Piper have any kind of relationships with helping xoma getting financed?
Did Piper participated in the last private placement? it has not been published to my knowledge. The previous Sutro involvement was at least clear.
I do not know, if any have the answer will be nice to know.
Piper involvement, if any beyond analyst coverage, is work, they look to be rewarded one way or another.
If I understand why they got involved, beyond what we knew for months about anticd11a, BECAUSE that they are involved is a powerful reason to pay attention, is a positive for xoma and I will like to know more, not just accept it.
Especially, when I am not giving the chance to participate cause the bulk of the gains were before the news (no kidding)so it made it even more unfair (no kidding, where am I from disneyland?)
I made realized gains (and losses, nice balance at the end not to painful, for the risk)not believing Sutro and their melnitchenko, neither xoma ceoperson and the rest of the bunch, but believing Bax will have a sound judgement and a commitment.
Bax judgement seems not so sound as Fda troubles show, and bax commitment remains to be seen.
Piper lack of coverage in bpi, and the ceoperson almost casual approach to it (maybe more trials and if so maybe next fall/winter season) just does not compute well to me.
(despite my frequent calls as xoma main hope is anticd11a, and not bpi)cause it is confirming precisely that.
Of course, anticd11a could turn into a huge business, in spite of competition, and I follow xoma looking for another opportunity in the upside, but never blind before, neither now.
Just answer my question about Piper motives, any on the board, thank you in advance.
Icos, I start posting about it when it was $27 to $30, I ride it ($33 to $47), now it is consolidating quite strong, and I am looking for my next entry point, hopefully low $40s, if I can get another under $35 position I will be in for long, long.
xoma strength before the Piper coverage was there clear, but I stay out, cause I had no reason beyond the obvious accumulation, it is still strong, of course the price is slowly going down, nice to pick if it goes down further, no rush, I can wait (plus there is DNA, bgen, nxtl, exds all my trades did well and lookin to pick more on the cheap right now, and I trust their future and leaders).
Bax has strong business, will it break its peak or fail, it seems there is distribution ongoing (before the whole market weakness of last 2 or 3 days, it remains to be seen if they will past its peak.
Icos peak was part of the biotech surge, wait out of its regular behavior. Then a big drop back to regular range, the pafase news came after big drop, and I have the time to go in, I even hesitate at $27 to $30, market was not responding to it, then I took the opportunity based on the strength of their pafase news, market followed in my favor.
That I like.
The opposite behavior above of xoma share prices, no. Actually the bax involvement was so strong event that despite the surge pre news there was time to get in (I did but could not believe it will go to $16, out at $10, back at $7 burn with Fda (this failure I do not blame xoma, I took the risk, despite my doubts on the lack of data, now I know why).
Mixing apples and oranges, you know as usual.
But, it is simple, keep the rotten apples and the rotten oranges to one side...
... and the good apples and oranges to the other...
made jelly out of the rotten ones...
made preseve out of the good ones...
My case rests, I now will wait.
(Serono also has an interferon in the European market, Biogen one is the best, better than Amgn, Chir, and the rest). |
